Abstract 155P
Background
Increased mean platelet volume (MPV), an early marker of platelet activation has been shown to be associated with the pathophysiology of various cancers. However, studies analyzing the prognostic effect of MPV [Disease free survival (DFS) and Overall survival (OS)] in carcinoma stomach are lacking. This study was done to analyze the effect of MPV on DFS and OS of resectable carcinoma stomach patients.
Methods
Retrospective analysis of the data of 143 consecutively resected gastrectomy patients between 2009- 13 was done. Associations between MPV and Clinicopathological factors were assessed. DFS and OS for 5 years were analyzed using the Kaplan-Meier curve.MPV of 10.5 femtolitres (fl) yielded maximum combined sensitivity and specificity on ROC curve. The area under curve(AUC) for MPV was 0.611. Therefore Preoperative cut-off value of MPV was taken as 10.5 fl. Differences between survival curves were tested for statistical significance using the log-rank test.
Results
Mean OS in the group with preoperative MPV < 10.5 vs > 10.5 was 59.3 vs 41.3 mts (95% CI = 58.81 – 60 vs 37.87 - 44.94; P = <0.0001). Mean OS in the group with postoperative (after one month) of MPV< 10.5 vs > 10.5 was 37.9 vs 29.2 mts (95% CI = 32-43.8vs 27.1- 19.8; P = <0.0001). Mean DFS in the group with preoperative MPV < 10.5 vs > 10.5 was 59.8 mts vs 38.2 mts (95% CI = 59.365-60.26 vs 31.798- 44.732; P = <0.0001). Mean DFS with postoperative (after one month) MPV< 10.5 vs > 10.5 58.0 mts vs 25.9 months (95% CI = 56.629 - 59.4 vs 20.841- 30.959; P = 0.012). These results show that MPV estimation both preoperatively and postoperative has a significant impact on both DFS and OS. And those patients who had increased MPV preoperatively had lower DFS and OS compared to those who had MPV lower at the initial presentation. Also, those patients who had initial high MPV which declined postoperatively after one month also had better DFS and OS compared to those who had persistent elevated MPV.
Conclusions
Hence MPV both preoperative and postoperative (1 month) shows to be a promising predictive factor in resectable carcinoma stomach.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
249P - Accuracy of endometrial biopsy by Pipelle: A systematic review and meta-analysis
Presenter: Jinhai Gou
Session: Poster display session
Resources:
Abstract
250P - Non-endometrioid endometrial cancer: Analysis of different adjuvant treatment modalities
Presenter: Gonçalo Nogueira da Costa
Session: Poster display session
Resources:
Abstract
251P - A prognostic index model for predicting long-term recurrence of uterine leiomyoma after initial myomectomy in women aged 18-44 years
Presenter: Xiu Ming
Session: Poster display session
Resources:
Abstract
252P - Uterine sarcomas in Qatar: Clinico-pathological characteristics and treatment outcome
Presenter: Ashraf Fadlelseid
Session: Poster display session
Resources:
Abstract
253P - Anti-PD-1-induced reinvigoration of tumour-infiltrating CD8+ T cells in epithelial ovarian cancer patients is correlated with T cell factor-1
Presenter: Junsik Park
Session: Poster display session
Resources:
Abstract
254P - Cyclin E1 is a shared biomarker of subsets of high grade serous ovarian cancer (HGSOC) and basal like breast cancer (BLBC)
Presenter: Diar Aziz
Session: Poster display session
Resources:
Abstract
255P - MEX3A is a prognostic biomarker and correlates with RNA splicing and cell proliferation in endometrial cancer by analysis of RNA-seq data
Presenter: Huining Jing
Session: Poster display session
Resources:
Abstract
256P - Lnc-AL445665.1-4 may be involved in the development of multiple uterine leiomyoma through interacting with miR-146b-5p
Presenter: E Yang
Session: Poster display session
Resources:
Abstract
257P - Treatment results of low risk gestational trophoblastic neoplasia (GTN) from a tertiary hospital, Chennai, India
Presenter: Rakesh M. P
Session: Poster display session
Resources:
Abstract
258P - Assessment of sexual health in patients treated for ovarian cancer
Presenter: Renu Madan
Session: Poster display session
Resources:
Abstract